BD Completes Bard Acquisition
January 2, 2018—BD (Becton, Dickinson and Company) recently announced it has completed the acquisition of CR Bard, Inc. The combined company, which will have approximately $16 billion in revenue, integrates Bard's 16,000 employees with BD's 65,000 employees.
A definitive agreement for the transaction was first announced in April 2017.
Bard Peripheral Vascular, a division of CR Bard, manufactures and markets devices for the treatment of peripheral and coronary artery diseases. Peripheral devices include the Lutonix 035 paclitaxel-coated balloon and the Atlas, Conquest, Dorado, and Ultraverse lines of percutaneous transluminal angioplasty balloons. For coronary interventions, Bard's portfolio includes the Bard Snare retrieval kit, the Porter hydrophilic guidewire for treatment of chronic total occlusions, and the True, True Flow, Vida BAV, and Vida PTV valvuloplasty balloon catheters.
With completion of the acquisition, Bard became a wholly owned subsidiary of BD.